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Purpose of the study
The Antiretroviral Pregnancy Registry (APR) is an inter-
national collaborative operation which utilizes a pro-
spective exposure-registration design to study
antiretroviral (ARV) drug exposures during pregnancy.
This study assessed the potential for human teratogenic
risk of atazanavir (ATV), a protease inhibitor used to
treat HIV infection in combination with other ARV
agents. ATV exposures are increasingly reported to the
APR in this population, reinforcing the need to better
understand the risk of birth defects.
Methods
The analysis population includes all prospectively
reported pregnancy exposures with complete exposure
and birth outcome data for HIV-infected women
enrolled in the APR from January 1, 1989 through Janu-
ary 31, 2010; the ATV subset includes those enrolled
since June 2003, when ATV received FDA approval.
The prevalence of birth defects after pregnancy ARV
exposure is compared both externally, with rates from a
population-based surveillance system, and internally
between first-trimester and combined second/third-tri-
mester exposures.
Summary of results
Through January 2010, 698 women with ATV-exposed
pregnancies were enrolled. The mean age of these
women was 29 years; 12.9% were White, 63.9% Black
and 16.7% Hispanic; 87.9% were from the US. 82.5% had
a baseline CD4 > 200 cells/mm
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pregnancies, 588 were eligible for analysis including 567
live births. Among 368 first trimester exposures (167
since 2008), 8 had birth defects (2.2%). The birth defect
rate in infants with second/third trimester exposures
was 2.5%, and the rate in a non-HIV-infected population
(CDC) was 2.72% (95% CI = 2.68-2.76). The risk of
defects of first trimester exposures relative to second/
third trimester exposures was 0.87 (95% CI = 0.29-2.61).
No pattern of birth defects suggestive of a common
etiology was observed.
Conclusions
Prevalence of birth defects among infants prenatally
exposed to ATV is not significantly different from inter-
nal and external comparison groups. These findings may
be useful in counseling patients who are exposed to
ATV during pregnancy.
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Table 1
Exposure to any ARV (Jan
1989-Jan 2010)
Exposure to ATV (Jun
2003–Jan 2010)
Earliest
exposure to
ARVs
First Trimester
# of defects/live
births
127/4563 8/368
Prevalence (95%
CI)
2.8% (2.3%-3.3%) 2.2% (0.9%-4.2%)
Second/Third
Trimester
# of defects/live
births
158/6184 5/199
Prevalence (95%
CI)
2.6% (2.2%-3.0%) 2.5% (0.8%-5.8%)
Any Trimester
# of defects/live
births
285/10747 13/567
Prevalence (95%
CI)
2.7% (2.3%-3.0%) 2.3% (1.2%-3.9%)
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